Fig. 4
Effect of GSK2334470 (GSK), PDK1 inhibitor, in MK-2206-resistant sublines compared with non-resistant cells. a Indicated cells were treated with GSK at indicated concentrations, with/without MK-2206 (5 μM) in RPMI1640 + 10 % FBS. Cell growth was evaluated as cell numbers at 72 h, and it was repeated three times. Data are expressed as the mean (±SD). b The effect of GSK on cell cycle phase distribution in LAN-1 and LAN-MK. LAN-1 and LAN-1-MK were treated with GSK (5 μM) with/without MK-2206 (5 μM) in RPMI1640 with 10 % FBS for 12 h followed by analysis of cell cycle phase distribution, as introduced in methods and material. Indicated cells were stained with PI for 30 min followed by FACScan flow cytometer. c IC50 of GSK in indicated cells